http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 18:34:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923068.html si-local-file:///var/storage/secattach/20260813/26923068.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923068.html Thu, 13 Aug 2026 18:34:00 -0400 O.04856707 RNAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923068.html si-local-file:///var/storage/secattach/20260813/26923068.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+BARCLAYS+PLC/26923068.html Thu, 13 Aug 2026 18:34:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html <p align="justify">FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading price of the Company’s common stock on the Nasdaq Global Market on their respective grant dates, and will vest over a four-year http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html Fri, 07 Aug 2026 07:00:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html <p align="justify">FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading price of the Company’s common stock on the Nasdaq Global Market on their respective grant dates, and will vest over a four-year http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html Fri, 07 Aug 2026 07:00:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html <p align="justify">FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading price of the Company’s common stock on the Nasdaq Global Market on their respective grant dates, and will vest over a four-year http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html Fri, 07 Aug 2026 07:00:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html <p align="justify">FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading price of the Company’s common stock on the Nasdaq Global Market on their respective grant dates, and will vest over a four-year http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26887287.html Fri, 07 Aug 2026 07:00:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Earnings/Cartesian+Therapeutics+%28RNAC%29+Tops+Q2+EPS+by+134c/26878602.html <p>Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.46, $1.34 better than the analyst estimate of ($0.88).</p><p>For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) <a href="http://www.streetinsider.com/ec_earnings.php?q=RNAC">click here</a>.</p> http://www.streetinsider.com/Earnings/Cartesian+Therapeutics+%28RNAC%29+Tops+Q2+EPS+by+134c/26878602.html Thu, 06 Aug 2026 07:10:55 -0400 RNAC http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cartesian+Therapeutics%2C+++For%3A+Jun+30/26878519.html si-local-file:///var/storage/secattach/20260806/26878519.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cartesian+Therapeutics%2C+++For%3A+Jun+30/26878519.html Thu, 06 Aug 2026 07:06:00 -0400 O.04856707 RNAC http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cartesian+Therapeutics%2C+++For%3A+Jun+30/26878519.html si-local-file:///var/storage/secattach/20260806/26878519.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Cartesian+Therapeutics%2C+++For%3A+Jun+30/26878519.html Thu, 06 Aug 2026 07:06:00 -0400 O.04856707 RNAC http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+Aug+06/26878473.html si-local-file:///var/storage/secattach/20260806/26878473.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+Aug+06/26878473.html Thu, 06 Aug 2026 07:04:00 -0400 O.04856707 RNAC http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+Aug+06/26878473.html si-local-file:///var/storage/secattach/20260806/26878473.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Cartesian+Therapeutics%2C+++For%3A+Aug+06/26878473.html Thu, 06 Aug 2026 07:04:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html <p align="center"><em>Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027 </em></p> <p align="center"><em>Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27</em></p> <p align="center"><em>Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27</em></p> <p align="center"><em>Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27</em></p> http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878419.html Thu, 06 Aug 2026 07:00:00 -0400 A.06822034 O.04856707 O.20026344 RNAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800716.html si-local-file:///var/storage/secattach/20260722/26800716.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800716.html Wed, 22 Jul 2026 13:11:00 -0400 O.04856707 RNAC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800716.html si-local-file:///var/storage/secattach/20260722/26800716.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Cartesian+Therapeutics%2C++++++++++++++++Filed+by%3A+JPMORGAN+CHASE+%26amp%3B+CO/26800716.html Wed, 22 Jul 2026 13:11:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html <p align="justify">FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html Thu, 02 Jul 2026 07:05:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html <p align="justify">FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 http://www.streetinsider.com/Press+Releases/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html Thu, 02 Jul 2026 07:05:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html <p align="justify">FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html Thu, 02 Jul 2026 07:05:00 -0400 O.04856707 RNAC http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html <p align="justify">FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company’s common stock with an exercise price of $10.18, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 http://www.streetinsider.com/Globe+Newswire/Cartesian+Therapeutics+Announces+New+Employment+Inducement+Grants/26723884.html Thu, 02 Jul 2026 07:05:00 -0400 O.04856707 RNAC